BIOMAT Database Logo BIOMAT Database Logo

Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach. 1991

G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA.

4'-deoxydoxorubicin (DxDx) was administered to 17 patients with locally advanced or metastatic gastric adenocarcinoma. Treatment cycles were repeated every 21 days. 15 eligible patients with a Karnofsky performance status of 50% or better (median: 70%) received at least one course of treatment; a median of 2 courses of DxDx was delivered (range 1 to 13). The median dose per treatment course was 26 mg/m2 (range 8.5 mg/m2 to 53 mg/m2). 69% of patients required dose reduction following the first course of therapy due to grade 3 or 4 myelosuppression, primarily neutropenia. The principal side effects included anemia, mild gastrointestinal toxicities, and alopecia; one patient experienced a 10% decrease in cardiac ejection fraction without clinical cardiac toxicity. Of the 15 patients assessable for response and toxicities, 1 patient had a partial response lasting 2.5 months. The median survival from the time of the first treatment was 3.3 months. We conclude that DxDx has only limited activity in the treatment of advanced gastric adenocarcinoma.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm

Related Publications

G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
January 1987, Investigational new drugs,
G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
July 1989, Investigational new drugs,
G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
February 1990, Investigational new drugs,
G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
June 1990, American journal of clinical oncology,
G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Phase I trial of esorubicin (4'deoxydoxorubicin).
September 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Phase I trial with 4'-deoxydoxorubicin (esorubicin).
January 1983, Investigational new drugs,
G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
November 1989, Investigational new drugs,
G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer.
August 1990, Investigational new drugs,
G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
A phase I-II trial of 4'-deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia.
April 1989, Clinical pharmacology and therapeutics,
G Somlo, and J Doroshow, and S Akman, and L Leong, and K Margolin, and M McNamara, and P Multhauf, and D Blayney, and R Morgan, and J Raschko
Phase II trial of 4'-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer.
January 1986, Investigational new drugs,
Copied contents to your clipboard!